This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
=== General information === "Pakistan". The World Factbook (2025 ed.). Central Intelligence Agency. Pakistan from UCB Libraries GovPubs Pakistan from BBC News Wikimedia Atlas of Pakistan Key Development Forecasts for Pakistan from International Futures Geographic data related to Pakistan at OpenStreetMap
Benzodiazepines such as flunitrazepam are lipophilic and rapidly penetrate membranes and, therefore, rapidly cross over into the placenta with significant uptake of the drug. Use of benzodiazepines including flunitrazepam in late pregnancy, especially high doses, may result in hypotonia, also known as floppy baby syndrome.
The biochemical mechanism of VOC generation in the human body is not fully comprehended. Their occurrence is due to changes in cell metabolism, inflammation, and oxidative stress, where reactive oxygen species (ROS) produced from cellular respiration interact with cellular structures (such as the membrane, proteins, DNA, and RNA) to create VOCs. The accumulation occurs in breath, skin, sweat, blood, urine, and faeces. The samples can be analyzed by various methods, such as selected-ion-flow-tube mass spectrometry (SIFT-MS), field asymmetric ion mobility spectrometry (FAIMS), nuclear magnetic resonance (NMR) spectroscopy, proton-transfer-reaction mass spectrometry (PTR-MS) and more, but the commonly used technologies are gas chromatography with mass spectrometry (GC-MS) and electric nose (e-nose). The difference in samples and methods of analysis chosen may explain the high heterogeneity observed in VOCs identified in different studies pertaining to the same diseases.
Sources: en.wikipedia.org
=== EC 2.7.3: Phosphotransferases with a nitrogenous group as acceptor === EC 2.7.3.1: guanidinoacetate kinase EC 2.7.3.2: creatine kinase EC 2.7.3.3: arginine kinase EC 2.7.3.4: taurocyamine kinase EC 2.7.3.5: lombricine kinase EC 2.7.3.6: hypotaurocyamine kinase EC 2.7.3.7: opheline kinase EC 2.7.3.8: ammonia kinase EC 2.7.3.9: phosphoenolpyruvate—protein phosphotransferase EC 2.7.3.10: agmatine kinase EC 2.7.3.11: now EC 2.7.13.1, protein-histidine pros-kinase EC 2.7.3.12: now EC 2.7.13.2, protein-histidine tele-kinase EC 2.7.3.13: glutamine kinase
In contrast to MRI, structural biology studies do not directly generate an image, but rely on complex computer calculations to generate three-dimensional molecular models. Currently most samples are examined in a solution in water, but methods are being developed to also work with solid samples. Data collection relies on placing the sample inside a powerful magnet, sending radio frequency signals through the sample, and measuring the absorption of those signals. Depending on the environment of atoms within the protein, the nuclei of individual atoms will absorb different frequencies of radio signals. Furthermore, the absorption signals of different nuclei may be perturbed by adjacent nuclei. This information can be used to determine the distance between nuclei. These distances in turn can be used to determine the overall structure of the protein. A typical study might involve how two proteins interact with each other, possibly with a view to developing small molecules that can be used to probe the normal biology of the interaction ("chemical biology") or to provide possible leads for pharmaceutical use (drug development). Frequently, the interacting pair of proteins may have been identified by studies of human genetics, indicating the interaction can be disrupted by unfavorable mutations, or they may play a key role in the normal biology of a "model" organism like the fruit fly, yeast, the worm C. elegans, or mice. To prepare a sample, methods of molecular biology are typically used to make quantities of protein by recombinant expression and purification from bacteria.
Conventions, festivals and large events were permitted, and all businesses, schools, and places of recreation could be fully open. On July 15, 2020, Pritzker announced a new COVID-19 mitigation plan in the event of a resurgence of COVID-19. The metrics that would be used to determine whether COVID-19's spread in a region required additional mitigations were a sustained increase in 7-day rolling average (7 out of 10 days) in the positivity rate; and one of the following: a sustained 7-day increase in hospital admissions for a COVID-19 or the reduction in hospital capacity. Another metric was three consecutive days averaging greater than or equal to 8% positivity rate.
== Further reading == Alexander, Mark, and John Sparry. Jump Commander: In Combat with the 82nd Airborne in World War II. Philadelphia: Casemate, 2010. ISBN 1-935149-28-8 OCLC 506253036 Angress, Werner T. Witness to the Storm: A Jewish Journey from Nazi Berlin to the 82nd Airborne, 1920–1945. Durham, NC: Miriam Angress, 2012. ISBN 1-4774-5701-1 OCLC 804824030 Anzuoni, Robert P. I'm the 82nd Airborne Division!: A History of the All American Division in World War II After Action Reports. Atglen, PA : Schiffer Publishing, 2005. ISBN 0-7643-2347-4 OCLC 62555533 Anzuoni, Robert P. The All American: An Illustrated History of the 82nd Airborne Division, 1917 to the Present. Atglen, PA: Schiffer Pub, 2001. ISBN 0-7643-1321-5 OCLC 49935879 Barry, Robert F. Power Pack: The Dominican Republic, 1965–1966. Portsmouth, Va: Messenger, 1965. OCLC 6655474 Baugh, James Emory. From Skies of Blue: My Experiences with the Eighty-Second Airborne During World War II. New York: iUniverse, 2003. ISBN 0-595-74982-8 OCLC 64584040 Breuer, William B. Drop Zone, Sicily: Allied Airborne Strike, July 1943. Novato, CA: Presidio, 1983. ISBN 0-89141-196-8 OCLC 9945654 Burriss, T. Moffatt. Strike and Hold: A Memoir of the 82nd Airborne in World War II. Washington, D.C.: Brassey's, 2000. ISBN 1-57488-258-9 OCLC 43903491 Caraccilo, Dominic J. The Ready Brigade of the 82nd Airborne in Desert Storm: A Combat Memoir by the Headquarters Company Commander. Jefferson, N.C.: McFarland, 1993. ISBN 0-89950-829-4 OCLC 27265069 Carter, Ross S. Those Devils in Baggy Pants. Cutchogue, NY: Buccaneer Books, 1996.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.